Checking the Effectiveness of Shorter Radiation Therapy for Prostate Cancer

Recruiting · Phase 3 · Prostate Adenocarcinoma and related conditions · 42 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at two types of radiation therapy for high-risk prostate cancer. One type is called stereotactic body radiation therapy (SBRT). It gives five treatments in two weeks using higher doses of radiation. The other is the usual radiation therapy, which is given over four to nine weeks with more treatments. Researchers want to see if the shorter treatment is just as effective at preventing cancer from coming back.

The trial's ID number is NCT05946213. This is a Phase 3 trial, which means it is looking at how well the treatments work and their safety. About 1,209 people are expected to participate.

Who can join

Men aged 18 and older can join this trial. They must have a confirmed diagnosis of high-risk prostate cancer. Other health issues may affect eligibility. The trial team will make sure each person meets the requirements before enrolling.

Conditions

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8

Age group

Adult, Older adult

Sex

Male

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly placed into one of two groups. In the first group, patients will receive SBRT with five treatments over two weeks. In the second group, they will receive the usual radiation therapy with 20 to 45 treatments over four to nine weeks. Everyone will have tests like scans and may provide blood and urine samples.